Traveller's diarrhoea vaccine - Emergent BioDefense Operations Lansing
Alternative Names: ACTIVAXLatest Information Update: 28 Nov 2007
At a glance
- Originator Emergent BioDefense Operations Lansing
- Developer Emergent BioDefense Operations Lansing; Johns Hopkins Bloomberg School of Public Health; Naval Medical Research Center; Nonindustrial source; Walter Reed Army Institute of Research
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Campylobacter infections; Escherichia coli infections; Shigella infections
Most Recent Events
- 28 Nov 2007 Discontinued - Phase-I for Shigella infections in USA (PO)
- 28 Nov 2007 Discontinued - Phase-II for Campylobacter infections in USA (PO)
- 28 Nov 2007 Discontinued - Preclinical for Escherichia coli infections in USA (PO)